5/27/2020 Label Matrix V7 02 02 Lz08
Label Matrix V7 02 02 Lz0 Keygen. Euro Plus Nice. L0pht AntiSniff v1.02.1 by FHCF.zip. Label Designer Plus DELUXE v7.3.0.0 Keygen. With v10.02 and later, you can customize the names used for the LIDAR classes found within LAS files by creating a lidarclasses.txt file in the Global Mapper installation folder and adding a line for each class number to override with a format of lidarclass,classname, like 3,'My Custom Class Name'.
![]()
Coordinating Presence in Women’s Health Market Misalignment = A Value Creation Opportunity Innovators seeking development partners to advance Large and mid-tier companies prefer to acquire or license products products to commercialization in women’s health. That are later-stage or ready for commercialization. Network of Product Developers Network of Potential Commercial Partners. Accelerating products to value inflection Strategic.Company names and logos are for illustrative purposes only. Science & Technologies Proof of Concept Late Stage Global Women's Health Market Worth $51 Billion by 2025 - CAGR: 3.9% 1 5 1.
Bacterial Vaginosis Symptoms & Causes of BV. BV is the most commonly reported vaginal infection in women ages 15- 44.1 BV is characterized by a shift in the vaginal flora from the dominant Lactobacillus to a polymicrobial flora.2. BV has been associated with serious health issues, including preterm births, pelvic inflammatory disease, increased susceptibility to sexual transmitted infections (including HIV infection) and other chronic health problems.1,2. A number of potential microbial pathogens, singly and in combinations, have been implicated in the disease process. The list of possible agents includes Gardnerella, Atopobium, Prevotella, Peptostreptococcus, Mobiluncus, Sneathia, Leptotrichia, Mycoplasma, and BV- associated bacterium 1 (BVAB1) to BVAB3.1 1. Center for Disease Control and Prevention (CDC). Www.cdc.gov/std/bv/stats.htm 15 2.
Onderdonk, A. “The Human Microbiome during Bacterial Vaginosis,” Clinical Microbiology Reviews, April 2016 Volume 29 Number 2. Bacterial Vaginosis Symptoms & Causes of BV. BV is characterized by the presence of three of the following four 2 criteria: Vaginal pH of 4.5 Clue cells on saline wet mount Release of a fish amine odor A characteristic thin, homogenous vaginal discharge ▪ In 1991, Nugent et al. Described a Gram stain scoring system of vaginal smears to diagnose BV.
1,3. The Nugent score is calculated by assessing for the presence of large gram-positive rods (Lactobacillus morphotypes; decrease in Lactobacillus scored as 0 to 4), small gram-variable rods (G. Vaginalis morphotypes; scored as 0 to 4), and curved gram-variable rods (Mobiluncus spp. Morphotypes; scored as 0 to 2) and can range from 0 to 10. A score of 7 to 10 is consistent with BV. 1,3.
BV is not considered to be a sexually transmitted infection, but it is more common in women who are sexually active. Sha, Beverly E., et al. “Utility of Amsel Criteria, Nugent Score, and Quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and Lactobacillus spp. For Diagnosis of Bacterial Vaginosis in Human Immunodeficiency Virus-Infected Women.“ JOURNAL OF CLINICAL MICROBIOLOGY, Sept. “Managing recurrent bacterial vaginosis.” Sexually Transmitted Infections.
2004; 80(1): 8–11. Bacterial Vaginosis Market Opportunity.
In the US, an estimated 21 million women aged 14-49 years (approximately 29%) are infected with BV.1,2 BV leads to symptoms including abnormal vaginal discharge and odor that are unpleasant and disrupt and interfere with a woman’s relationships and general quality of life. BV has been associated with serious health issues, including preterm births, pelvic inflammatory disease, increased susceptibility to sexual transmitted infections (including HIV infection) and other chronic health problems.3,4 IMS/IQVIA ▪ According to IMS/IQVIA data, the 2016 U.S. Annual sales figures for BV prescriptions were in excess of $150m for vaginal forms of Clindamycin and Metronidazole.5 Lupin Inc., the U.S. Subsidiary of India-based Lupin, acquired Symbiomix, the maker of secnidazole (a 5-nitroimidazole antibiotic granular powder) for the treatment of BV in a transaction valued at $150m.6 ▪ Lupin’s 1x oral Solosec® (secnidazole) launched in May of 2018.7 1. Sucher, Allana et al., “Bacterial Vaginosis: A Review,” US Pharmacist 2018: 43(9):32-33 3.
Center for Disease Control and Prevention (CDC). Www.cdc.gov/std/bv/stats.htm 4. Onderdonk, A.
“The Human Microbiome during Bacterial Vaginosis,” Clinical Microbiology Reviews, April 2016 Volume 29 Number 2 5. MS/IQVIA data (2016). Data on file 17 6. New Contraceptive Option Ovaprene® Overview Innovation in Contraception Advances in hormone products have largely focused on reducing the hormone dosage, adjusting or extending the duration of protection and optimizing methods of administration. 1 2 3 4 Convenience is driving new innovation.
NuvaRing®. Monthly, convenient vaginal ring product form. 2017 worldwide sales: $761 million (Merck)5. Mirena® Product Family.
Physician inserted, long-acting. Low/locally delivered hormone IUS. 2017 worldwide sales: $1.12 billion (Bayer)7 1.
Lo Loestrin Fe contains a low-dose combination of two female hormones. Lo Loestrin® and its design are registered trademarks of Allergan Pharmaceuticals International Limited. Minastrin Minastrin® is a registered trademark of Allergan Pharmaceuticals International Limited. Annual Report on Form 10-K for fiscal year ended December 31, 2017 22 6.
Bayer Annual Report 2017. Includes sales for Mirena®, Kyleena® and Jaydess® / Skyla®. New Contraceptive Option Ovaprene® Overview Women’s Preferences. Effective Pregnancy Prevention. Convenient Product Forms.
Independent surveys revealed that the vaginal ring has many of the features women deemed extremely important.1. Less Hormones. A majority of women prefer a monthly option with a lower hormone dose than the pill.2. Methods not in the moment (noncoital). 77% of women who practice contraception currently use non-coital (not in the moment) methods.3 1.
Lessard, L,Perspectives on Sexual and Reproductive Health, Volume 44, Number 3,9-2012 23 2. Hooper, DJ, Clin Drug Investig. 2010;30(11):74963 3. What’s Missing in Contraception? Hormone free alternatives that are effective and easy to use Least Effective Hormone Free Product Landscape1 Marketed or in development Spermicides / Vaginal Gels 1,2 Effectiveness (72% Typical Use) Woman controlled Used “in the moment” Condoms Effectiveness (82% Typical Use) Not woman controlled Used “in the moment” Diaphragms Effectiveness (88% Typical Use) Woman controlled Used “in the moment” Long-acting IUD Effectiveness (99% Typical Use) Most Effective Not woman controlled Physician inserted 1.
Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Technology: Twentieth Revised Edition. New York, NY: Ardent Media, 2011.
New Contraceptive Option Ovaprene® Overview Ovaprene successfully prevented sperm from reaching the cervical canal in a previous human postcoital test (PCT) clinical study. 2009 - Postcoital Assessment:1. Open-label, single-arm, pilot safety and tolerability study. 2,3. Published in the Journal of Reproductive Medicine, 2009. Patients:. N= 20; all women completed one cycle of use.
Results:. Postcoital testing revealed no viable sperm in the cervical mucus. No colposcopic abnormalities, no significant changes in vaginal flora and no serious adverse effects observed. In PCT studies of similar size, products (diaphragms) with no motile sperm in the cervical mucus during their PCT assessments demonstrated “typical use” contraceptive effectiveness of 88% in pivotal contraceptive studies evaluating pregnancy rates over time.
Journal of Reproductive Medicine 2009; 54: 685-690 2. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Technology: Twentieth Revised Edition. New York, NY: Ardent Media, 2011.
New Contraceptive Option Ovaprene® Overview U.S. Regulatory Strategy. PMA with CDRH (Medical Device Division) as lead review division. Pathway expected to be based on similar CDRH approvals - Example: Caya® diaphragm. Step 1 – Postcoital test (PCT) 2018 / 2019. Step 2 – Pivotal Study 2020 / 2021.
The study is enrolling 50 couples. Single pivotal clinical (expected).
25 women complete a total of 21 visits. N= 250 completers over 6 months of use. Evaluated over the course of five menstrual cycles. Primary Endpoints: Safety & Efficacy. Each woman’s cervical mucus will be examined at several points during. Pregnancy probability.
The study:. Secondary Endpoints:. Cycle 1 - Baseline (excludes the use of any product),. Acceptability/product fit/ease of use.
Cycle 2 - Use of a barrier method (diaphragm),. Assessments of vaginal health. Cycles 3,4 and 5 - Ovaprene vaginal ring. Assess motile sperm per high powered field (HPF) in the cervical mucus, post coitus. Safety assessments, PK, acceptability, fit, and ease of use. Data from the study is expected to be available in the second half of 2019.
If there is demonstration of feasibility in the PCT clinical trial, the Company intends to prepare and file an Investigational Device Exemption (IDE) with the FDA to commence a pivotal clinical trial to support marketing approvals of Ovaprene in the United States, Europe and other countries worldwide. 27.Anticipated regulatory pathway and timelines. Daré has not had any communications with the FDA regarding the specific PMA requirements for Ovaprene. New Contraceptive Option Ovaprene® Overview Features Desired Most in Birth Control:1-4 Design Features of Ovaprene:5,6 + Convenience Monthly Ring Product Form (Easy to Use & Easy to Remember) Women chose rings for the convenience of a non-daily option. + Hormone Free No Hormones in the API Unique dual action MOA (spermiostatic & barrier). + Efficacy Expected Typical Use Effectiveness Comparable to Hormone Contraception (88% vs 91%). + Favorable Side Effect Profile No Colposcopic Abnormalities No significant changes in vaginal flora.
No serious adverse effects observed in prior published study. + Easily Manage Fertility No Systemic Activity Inserted and removed without a provider. Immediate return to fertility. Lessard, L,Perspectives on Sexual and Reproductive Health, Volume 44, Number 3,9-2012 3. Hooper, DJ, Clin Drug Investig. 2010;30(11):74963 4. Ersek, J, Matern Child Health J (2011) 15:497–506 5.
Journal of Reproductive Medicine 2009; 54: 685-690 28 6. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M.
Contraceptive Technology: Twentieth Revised Edition. New York, NY: Ardent Media, 2011. Female Sexual Arousal Disorder (FSAD) Sildenafil Cream, 3.6% Successful Proof of Concept. Sildenafil Cream, 3.6% improved genital blood flow in a proof-of-concept study (n=31):1.
Efficacy signal observed in both pre and postmenopausal patients. Excellent systemic/local safety and tolerability profile 505(b)(2) Regulatory Pathway. Ability to leverage the safety profile of sildenafil (Viagra®) for FDA submission package Attractive Market Opportunity2. 33% of females in the U.S. (21 to 60 years old) experience symptoms of low or no sexual arousal.
16% (10m women) are considered distressed and are seeking a solution to improve their condition Patent Coverage. Patents covering the licensed technology have been granted with terms through 2031 (through June 2029 in the U.S.). No ANDA route: ANDA is not currently an option for topicals that result in low systemic uptake 30 1.
Data on file 2. Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. Based on US Census projections for 2016. Female Sexual Arousal Disorder (FSAD) Sildenafil Cream 3.6% Hypoactive Sexual Female Sexual Vulvar-Vaginal Dyspareunia Desire Disorder Arousal Disorder Atrophy (HSDD) (FSAD) No Approved Products With its approval of Addyi®, FDA has now acknowledged and formally classified the distinct and separate disorders that comprise Female Sexual Dysfunction. Where HSDD is characterized primarily by a lack of sexual desire, FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal.
INTRAROSA is a registered trademark of Endoceutics, Inc. Imvexxy is a trademark of TherapeuticsMD, Inc. Osphena is a registered trademark of Duchesnay USA, Pennsylvania, USA. ESTRACE® is a registered trademark of Allergan Pharmaceuticals International Limited. Premarin is a registered trademark of Pfizer Inc. Addyi is a registered trademark of Sprout Pharmaceuticals, Inc.
31. Bremelanotide is a registered trademark of Palatin Technologies, Inc. Female Sexual Arousal Disorder (FSAD) Sildenafil Cream 3.6% FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal; it is also characterized by distress or interpersonal difficulty. Estimated 23-33% of women suffer from arousal disorder:. Meta-analysis of 95 studies from 2000-2014 indicated the prevalence of Female Sexual Dysfunction in premenopausal women worldwide is 40.9%, and difficulty with arousal alone is 23%.1.
33% of women in the U.S. Age 21 to 60 (approximately 20 million women), experience symptoms of low or no sexual arousal.2,3. 10 million women are considered distressed and actively seeking treatment.2.Diagnostic and Statistical Manual 4th Edition Text Revision (DSM IV TR), defines female sexual arousal disorder as a persistent or recurrent inability to attain or to maintain until completion of the sexual activity, an adequate lubrication-swelling response of sexual excitement. The diagnostic criteria also state that the inability causes marked distress or interpersonal difficulty, is not better accounted for by another Axis I disorder (except another sexual dysfunction), and is not due exclusively to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition. McCool et al.
Sex Med Rev 2016;4:197-212. Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. Based on US Census projections for 2016. Female Sexual Arousal Disorder (FSAD) Sildenafil Cream 3.6% Formulation Innovation.
Sildenafil Cream, 3.6% designed to directly increase local blood flow to the genital tissue. The formulation delivers localized action, with minimal systemic uptake of the active drug.1 SST Formulation Technology 6 issued patents in the U.S.
On the topical delivery of Sildenafil and other PDE-5 inhibitors. Leveraging the known therapeutic benefit of oral sildenafil to stimulate increased blood flow to the genital tissue. If approved, Sildenafil Cream, 3.6% may offer a safe, effective and ‘on demand’ solution to difficulties with sexual arousal. Data on file. Female Sexual Arousal Disorder (FSAD) Sildenafil Cream, 3.6% Sildenafil C T AUC Treatment N max max last Phase 1 Study of SST-6007 (Sildenafil Cream, 3.6%)1 Single Dose (ng/ml) (hr) (h.ng/ml). Normal healthy postmenopausal women were dosed with Topical Sildenafil 20 35 mg 3.4 2.37 25.6 escalating doses of Sildenafil Cream, 3.6%, using a cross- 1 g of cream over study design. Female Sexual Arousal Disorder (FSAD) Sildenafil Cream 3.6% Phase 2b Program: Continue to explore additional clinical and non-clinical work that might be valuable or required to support the overall program and the anticipated design of the Phase 2b.
Content Validity Planned Type C Meeting At Home Study 2b At Home Study Initiation Anticipated 2019 Initiated (4Q 2018) 2019 Topline Data – 4Q 2020. A content validity study is designed to help ensure. We will request at Type C meeting. The Phase 2b at-home study will the concepts we plan to measure are the most to get feedback on whether the allow patients to use the important and relevant to our target population.
Agency agrees that the patient investigational product and placebo reported outcomes (PRO) in their home setting. This is a non-interventional study – participants will instruments are content valid for not be asked to use or evaluate any products. The FDA is agreeable to a 12-week the target population. Phase 2b for Sildenafil Cream, 3.6% to assess reasonable safety and preliminary efficacy. The 2016 Draft Guidance reflects expectations regarding phase 3 study length and patient population. Key Takeaways:.
The phase 2b program will consist of a content validation component followed by at-home dosing of the investigational product and a placebo control. The plan is to use the selected PRO instrument and FDA agreed upon endpoints for the phase 2b and phase 3 clinical trials. Female Sexual Arousal Disorder (FSAD) Sildenafil Cream 3.6% Hypoactive Sexual Female Sexual Vulvar-Vaginal Dyspareunia Desire Disorder Arousal Disorder Atrophy (HSDD) (FSAD) Sildenafil Cream, 3.6% (If approved) With its approval of Addyi®, FDA has now acknowledged and formally classified the distinct and separate disorders that comprise Female Sexual Dysfunction. Where HSDD is characterized primarily by a lack of sexual desire, FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal. INTRAROSA is a registered trademark of Endoceutics, Inc.
Imvexxy is a trademark of TherapeuticsMD, Inc. Osphena is a registered trademark of Duchesnay USA, Pennsylvania, USA. ESTRACE® is a registered trademark of Allergan Pharmaceuticals International Limited. Premarin is a registered trademark of Pfizer Inc. Addyi is a registered trademark of Sprout Pharmaceuticals, Inc.
37. Bremelanotide is a registered trademark of Palatin Technologies, Inc. Intravaginal Ring (IVR) Technology Platform Daré has an exclusive, global license to Juniper’s novel IVR technology originally developed by Dr.
Robert Langer from MIT1 and Dr. William Crowley2 from Massachusetts General Hospital and Harvard Medical School. Daré’s exclusive license covers all rings in development as well as additional applications of the IVR technology platform in other therapeutic areas.. Features of the Juniper intravaginal ring technology include:.
Sustained drug delivery. Variable dosing and duration. Single or multiple drug delivery via a solid ethylene vinyl acetate polymer matrix (without the need for a membrane or reservoir to contain the active drug or control the release). Current 505(b)(2) candidates licensed from Juniper include:. DARE-OAB1.
Formerly JNP-0101, an oxybutynin ring for the treatment of overactive bladder;. DARE-HRT1. Formerly JNP-0201, a combination bio-identical estradiol + progesterone ring for hormone replacement therapy. DARE-FRT1. Formerly JNP-0301, a natural progesterone ring for the prevention of preterm birth and for fertility support as part of an IVF treatment plan. Hormone Replacement Therapy (HRT) DARE-HRT1 HRT remains the most effective treatment for vasomotor symptoms 4 (VMS) and the genitourinary syndrome of menopause (GSM) and has $2.2 Billion U.S. Market been shown to prevent bone loss and fracture.1.
45M women in U.S. Approaching or in menopause.2. 2012 NAMS consensus statement supports HRT in peri- and post- menopausal women – estrogen to reduce symptoms and progesterone $660M $1.5 B to prevent thickening of uterine wall.3 FDA- Compounded approved. NAMS recommends non-oral route over oral.3.
2002 Women’s Health Initiative (WHI) study showed that the long-term use of certain synthetic hormones (a combination of medroxyprogesterone and conjugated equine estrogens) increased the risk of breast cancer, stroke, heart attack and blood clots Compounded FDA-approved 1. The 2017 hormone therapy position statement of The North American Menopause Society; Menopause: The Journal of The North American Menopause Society Vol.
Census Bureau, Population Division. 2015 to 2060 (NP2012-T2).
Released Dec. Menopause, Vol. Source: Symphony Health Solutions Report. Hormone Replacement Therapy (HRT) DARE-HRT1 Phase 1 - Hormone Replacement Therapy (HRT) DARE-HRT1 for the treatment of VMS due to menopause – combination bio-identical estradiol and progesterone in a convenient 28 day IVR.
Proposed Study:. A Phase 1, Open-Label, 3-arm Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 (80 µg and 160 µg Estradiol/ 4 mg and 8 mg Progesterone Intravaginal Rings) in Healthy Post-Menopausal Women. Primary Objectives:. To describe the PK parameters over 28 days using two different dose combinations of DARE-HRT1 Intravaginal ring (IVR): Estradiol 80 µg/Progesterone 4 mg IVR Estradiol 160 µg/Progesterone 8 mg IVR. Identify the steady-state PK after 28 days of each DARE-HRT1.
N=30 41. A New Contraceptive Target DARE-RH1 CatSper A Novel Approach To Male And Female Contraception. The identification of the CatSper target represents the potential to develop a novel class of non-hormonal contraceptive products for both men and women. The discovery of a sperm-specific ion channel, CatSper, was validated in animal models where it was demonstrated that male mice lacking CatSper have poor sperm motility. CatSper proteins are ion channels expressed solely in the membranes of sperm flagellum and are essential to sperm motility.
Pre-clinical research has demonstrated CatSper mediates hyperactive motility of sperm. Sperm hyperactivity is necessary to penetrate the physical barrier known as the zona pellucida which encloses the ovum and protects the egg.1. The contraceptive benefit of targeting CatSper is achieved by inhibiting sperm hyperactivity and preventing egg fertilization. A New Long Acting Contraceptive Option Microparticle 6 & 12 Month Injectable Contraception ORB-204 and ORB-214, injectable etonogestrel1 The initial development on Orbis’ long-acting injectable contraceptive program was carried out under a subcontract funded by Family Health International (FHI 360) through a grant from the Bill & Melinda Gates Foundation. Pre-clinical studies for the 6- and 12- month formulations have been completed to date: Establishing pharmacokinetics and pharmacodynamics profiles. An injectable contraceptive is designed to provide discreet, non-invasive protection over several months. Limitations of the currently marketed injectable contraceptive: provides contraceptive protection for only three months, and can delay the ability to get pregnant for up to ten months after receiving the injection.
![]()
Target product profile of long-acting injectable. Prolonged duration (6 to 12 months), improved ease of use, with an improved side effect profile and predictable return to fertility. Data on file. Bacterial Vaginosis Market Insights American Sexual Health Association (ASHA), in conjunction with Harris Poll, conducted a national survey of 304 women ages 18 to 49 who have had bacterial vaginosis (BV). The survey was conducted online by Harris Poll on behalf of Symbiomix Therapeutics, LLC, a Lupin company, and the ASHA within the United States between September 14 and 29, 2017 among 304 US women aged 18-49 who have been diagnosed by a healthcare professional with BV within the past 2 years (“women with bacterial vaginosis”). US Contraceptive Population is Over 60 million and Continues to Grow Total US Females Age 15-44 (Millions) 69 68 68.0 68.1 68.1 67.8 67.6 67.5 67 67.3 67.2 67.0 66.8 66.7 66.5 66 44 (MM) 44 - 66.2 65.8 65 65.4 65.0 64.6 Females age 15 age Females 64 64.2 63.9 63.6 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Year Source: US Census Bureau, 2017 National Dataset (2016 is base population estimate for projection) Dare Bioscience – Ovaprene Market Assessment, Jan 2019 54.
Brand Contraceptives Have Consistently Increased in Price Average Price/Cycle (28 days) for Branded CHCs ($WAC) – As of Jan 2019 $170.00 $160.47 $160.00 $152.50 $150.00 $140.03 $140.00 $129.51 $130.00 $115.40 $120.00 $110.00 $100.64 $100.00 $88.88 $90.00 $81.95 $76.41 $80.00 $68.02 $70.00 $58.94 $60.00 $50.34 $45.57 $50.00 $41.53 $37.03 $40.00 $30.00 $20.00 $10.00 $0.00 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Avg Annual Increase 7.6% 12.2% 8.3% 10.7% 20.6% 13.9% 13.6% 8.4% 8.8% 13.7% 14.7% 12.1% 9.4% 9.6% 6.5% Source: MediSpan PriceRx, accessed Jan 2019. Average of 13 available branded contraceptives available in US market. Only three of these brands have no generic equivalent, and the average price/cycle for those 3 = $171.06 Dare Bioscience – Ovaprene Market Assessment, Jan 2019 58. Over 70% of Reproductive-Aged Women in the US Have Private Insurance Trend in Insurance Coverage Over Time (Age 19-44) 80% 71% 71% 69% 70% 65% 60% 44 - 50% 40% 30%% of% Pop US Age 19 21% 20% 21% 21% 20% 18% 17% 14% 14% 10% 0% 2013 2014 2016 2017 Private Government Uninsured.Patients can have more than one form of insurance, so totals may exceed 100%) Source: Berchick et al.
US Census Bureau, Health Insurance Coverage in the US: 2017, Issued Sep 2018 Dare Bioscience – Ovaprene Market Assessment, Jan 2019 59. GRAPHIC3darbioscienceoverview030001.jpgbegin 644 darbioscienceoverview030001.jpgMCX 02D9)1@!
#VP!#,' @,' @,# P,$ P,$!0@%!00$M!0H'!P8(# H,# L.' PL-#A(0#0X1#@L+$!80$1,4%145# 7&!84&!(4%13MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04M%!04%!04%!04%!04%!04%!04%!04%!3P 1' )! 0$ $' P0%!@KQO/T?;W^/GZ0 'P$ P$! 0 $' P0%!@+!T4ZSX,)O XJN)BG/-299VKJC%,+G;P?$CQ9)C/BG6O!A+%5JVM?Q#4NP!3ZQ^.H2P#Q5GVGCKQ-LR?$NKGMMEP#BJHZAX4YPGB;6 3P!/O 57'6L$X7?P.TO-695.^E^.J'XU2D9X2+53VM2 Q5NOZIX&R? Q5 G6TH!QFIE3BD:QFUNSKE;(3S'M3#)/M (JIXO&OB#J=?U/CIDP#BJY=I%R',U'+MLFO.G339UQF:L3A.-=.'
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
IH?:R;WQ'=6BNQNYN/^FK?XUPD?Q!AF3Y9R:36RL,%NHKHKX?V'LT=@4)MQUNS8L=?OH93 /?UO:9-XNN(YCBG/ &U/^-41DXK6.'
![]() Comments are closed.
|
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
March 2023
Categories |